Form 4: Whitehawk Therapeutics Director Emma Reeve Granted 40,006 Stock Options

Whitehawk Therapeutics, Inc. Director Emma Reeve was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

Summary

• Emma Reeve, a Director of Whitehawk Therapeutics, Inc. (WHWK), was granted 40,006 stock options.
• The stock options have an exercise price of $2.04 per share.
• The grant date for these options is June 12, 2025.
• The options are subject to a vesting schedule where 100% of the shares will vest on the earlier of (i) the one-year anniversary of the grant date (June 12, 2026) or (ii) the day immediately prior to the next annual meeting of stockholders following the grant date.
• The options expire on June 12, 2035.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Emma Reeve beneficially owns 40,006 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive step for aligning management incentives with shareholder interests, though it is a routine compensation event and does not indicate significant new operational or financial developments.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The options are granted under the Issuer's 2021 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Risks

• The vesting of the options is contingent on the Reporting Person continuing to be a Service Provider, meaning forfeiture could occur if this condition is not met.
• The value of the stock options is dependent on the future market price of Whitehawk Therapeutics, Inc. common stock exceeding the exercise price of $2.04; if the stock price remains below this, the options may become worthless.

Future Outlook

The grant of stock options with a vesting schedule indicates a future commitment from the director to the company's performance, as the full benefit of the options is realized upon vesting, which is tied to continued service.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as other publicly traded sectors, to attract, retain, and incentivize key personnel by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology and healthcare sectors.
• The vesting schedule, tying full vesting to one year of service or the next annual meeting, is a typical short-to-medium term incentive structure for director equity grants.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director, Emma Reeve, constitutes a transaction with a related party, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused efforts on increasing stock price.
• Employees: While not directly impacting employees, the use of an equity incentive plan can set a precedent for broader employee equity compensation programs.

Next Steps

• The stock options will vest according to the specified schedule (earlier of one-year anniversary of grant or day prior to next annual meeting).
• Emma Reeve may choose to exercise the vested options at any time before their expiration date of June 12, 2035, assuming the stock price is favorable.

Key Dates

Recommendation

Keywords

Whitehawk Therapeutics, WHWK, SEC Form 4, Stock Option Grant, Insider Transaction, Director Compensation, Equity Incentive Plan, Emma Reeve